CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 26 enrolled
Drug / intervention
MK-4618 +3 moredrug
Likely dose
MK-4618 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01337674
NCT01337674Phase 1Completed
CompareCT.gov

A Study to Evaluate the Co-Administration of MK-4618 With Antihypertensive Agents

Merck Sharp & Dohme LLC·interventional·Posted Apr 19, 2011·Updated Dec 24, 2018

In Brief

A Phase 1 clinical trial evaluating MK-4618, Placebo for MK-4618, and 2 other interventions for Hypertension. Completed, enrolled 26 participants.

Detailed Summary

This study will evaluate the safety and tolerability of MK-4618 when coadministered with antihypertensive agents and will evaluate changes in blood pressure following co-administration of MK-4618 with a beta blocker and a vasodilator. The primary hypothesis of the study is that MK-4618 does not result in a clinically meaningful change in systolic blood pressure relative to placebo when co-administered with a beta-blocker or with amlodipine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 19, 2011
Enrollment StartApr 1, 2011
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.2 years ago

Interventions

MK-4618drug

Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7

Placebo for MK-4618drug

Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7

Metoprololdrug

Previously prescribed daily dose of open-label metoprolol for the duration of the study

Amlodipinedrug

Previously prescribed daily dose of open-label amlodipine for the duration of the study